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risen by more than 50% in real terms between 
2000 and 2009 among OECD countries [12], 
resulting in pharmaceutical expenditure as 
high as 60% of total health care expenditure 
in some countries [14,15]. In Europe, phar-
maceutical expenditure averaged 17.5% of 
INTRODUCTION
Pharmaceutical expenditure has been rising 
during the past decade with growth rates up 
to 13% per annum, which is typically greater 
than other components of health care [1-13]. 
Overall, expenditure on pharmaceuticals has 
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ABSTRACT
INTRODUCTION: Reforms have been introduced across Europe to increase prescribing ef-
ficiency with existing drugs. These include measures to lower prices of generics as well as in-
crease their prescribing versus originators and patented products in a class or related class. This 
is essential to maintain comprehensive health care in Europe given continued pressures. The al-
ternative is insufficient funds for new innovative drugs and increasing drug volumes with ageing 
populations. OBJECTIVE: To review the influence of measures and initiatives to increase the 
prescribing and dispensing of generics at low prices on ambulatory care prescribing efficiency. 
In view of this, provide guidance as authorities strive to introduce further reforms to meet their 
goals. METHODOLOGY: A narrative review of published papers combined with case histories. 
RESULTS: The different supply- and demand-side measures have reduced generic prices to 
as low as 2% to 3% of pre-patent loss prices in some cases as well as appreciably enhanced 
their utilisation. As a result, prescribing efficiency has increased without compromising care. In 
some cases, the reforms have led to expenditure actually falling despite appreciably increased 
volumes. CONCLUSIONS: Increasing use of generics at low prices will help maintain the Eu-
ropean ideals of comprehensive and equitable health care. However, countries will continually 
need to learn from each other.
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further enhance their prescribing efficiency 
as they struggle to meet patient demands, 
especially with pharmaceutical budgets now 
being cut in some countries [12,35,36]. This 
has been recognised by High Level Pharma-
ceutical Forums and the European Commis-
sion, both emphasising the need for increased 
use of generics, with competition enhancing 
the potential for lower prices for generics in 
order that more patients can be treated within 
target budgets [11,40,71-73]. In addition, 
potentially liberating monies to fund new 
innovative drugs [6-11,40,71,72]. However, 
this philosophy has not always been followed 
by individual companies, some of whom try 
and manipulate the market to maintain sales 
of their originator products for as long as 
possible [6,52,54,74]. The World Health Or-
ganization (WHO) also endorses the use of 
generics when discussing the rational use of 
medicines as well as potential strategies to re-
lease resources to help maximise health gain 
with available budgets [17,40,63,70,75]. This 
is different to the instigation of outpatient 
tendering for pharmaceuticals to help reduce 
costs, which may also include generics [13].
The various initiatives can be divided into 
supply-side reforms and demand-side re-
forms. Supply-side reforms include measures 
to lower the price of generics, accelerate 
their marketing authorisation, reference pric-
ing for the molecule (Anatomical Therapeu-
tic Classification – ATC – Level 5 [76]), the 
class (ATC Level 4) or the therapeutic area 
(ATC Level 3), as well as compulsory price 
cuts when target budgets are being exceed-
ed [1-8,10,11,14,15,31-35,37,38,40-42,44, 
52,77,78].
Demand-side measures include those to en-
hance the prescribing, requesting and dis-
pensing of generics versus originators, as 
well as enhance the prescribing of generics 
in a class or related class versus still patent-
ed products where all drugs in the class are 
seen as essentially similar for all or nearly all 
patients [1-11,15,31-38,41-53,63]. This in-
cludes the promotion of lower cost medicines 
where generics are available in a class, e.g. 
Belgium and Germany [11,31,40,53,66].
Patient care should not be compromised with 
increased use of generics versus originators 
apart from a small number of well known ex-
amples [3,4,6-8,10,15,37,38,41,79,80]. 
These include cyclosporine, lithium, certain 
long acting calcium channel blockers as well 
as some morphine preparations [31,41,79,80]. 
This is because in Europe generic medicines 
have to demonstrate the same qualitative and 
quantitative composition and the same phar-
maceutical formulation and bioavailability 
as the originator medicine to receive market 
total health care expenditure in 2009, rang-
ing from 7.3% in Denmark to 32.6% in 
Hungary [12,16,17]. This is set to continue 
unless addressed, driven by well recog-
nised factors including strict clinical targets, 
changing demographics with ageing popula-
tions, the continued launch of new premium 
priced drugs and rising patient expectations 
[1-5,7,8,12,15,18]. New cancer drugs are a 
particular concern with cancer rates rising, 
cancer now seen as a chronic disease through 
advances in treatments, the acquisition costs 
of cancer drugs typically higher than average 
drug costs, and new cancer drugs currently a 
significant proportion of new drugs in devel-
opment, estimated currently at over 350, with 
some new cancer drugs being launched at ap-
proximately US$10,000 per month [18-30]. 
As a result, health authorities and health in-
surance companies across Europe have in-
stigated multiple reforms to slow down this 
growth in expenditure, or even reverse it, to 
maintain the European ideals of equitable 
and comprehensive health care [1-11,15,31-
54]. The alternative is no or reduced funding 
for new innovative premium priced drugs 
as authorities struggle to stay within agreed 
budgets during this current financial situa-
tion, and greater acknowledgement of op-
portunity costs, which is already happening 
[6,9,12,35,55-57]. This is not in the best in-
terest of all major stakeholder groups. The 
reforms and initiatives include measures to 
enhance prescribing efficiency for both new 
and existing drugs. Initiatives for new drugs 
include the development of new models to 
help optimise their use, which centre on three 
pillars. The three pillars include horizon scan-
ning and budgeting pre-launch, critical drug 
evaluation peri-launch including possible 
risk-sharing arrangements, as well as moni-
toring of prescribing against agreed guidance 
post launch and, where possible, patient reg-
istries to assess the effectiveness and safety 
of new drugs in routine care [18,19,58-65].
Considerable effort has been directed to-
wards enhancing the prescribing efficiency 
of existing drugs, based on generics [1-
11,15,33,40,66]. This especially with global 
sales of pharmaceutical products likely to 
lose their patents between 2008 and 2013 
estimated at US$50-100bn (€35-70), and 
US$255bn between 2011 and 2016, out of 
total pharmaceutical sales of US$820bn in 
2009 (€579bn) including US$700bn from 
OECD countries [6-10,15,67-69], and ge-
neric substitution estimated to reduce costs 
to patients by an average of 60% in middle 
income countries alone [17,70]. As a result, 
present considerable opportunities for Eu-
ropean countries to learn from each other to 
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(Angiotensin Converting Enzyme Inhibitors 
– ACEIs – and Angiotensin Receptor Block-
ers – ARBs). This can be seen by health au-
thorities and health insurance companies be-
lieving:
 - PPIs [1,2,4-10,15,31,37,38,41-43,46,49, 
53,63]: all PPIs seen to have similar ef-
fectiveness.
 - Statins [1,2,4-10,37,38,41-43,45-47,49, 
63,88-93]: no appreciable difference be-
tween generic statins such as simvastatin 
and patented statins, atorvastatin and ro-
suvastatin, in the vast majority of patients. 
This is endorsed by IDEAL study, which 
failed to show a significant reduction in 
coronary vascular events for patients pre-
scribed high dose atorvastatin (80 mg/
day) versus low dose simvastatin (20mg/
day), and a recent meta-analysis dem-
onstrating that at comparable doses all 
statins appear therapeutically equivalent 
in reducing LDL-C levels. A recent eco-
logical study also showed that outcomes 
in terms of the subsequent impact of drug 
treatment on lipid levels were similar 
whether patients were prescribed formu-
lary drugs (including generic simvastatin) 
versus non-formulary drugs including 
patented statins. Published studies have 
also shown that patients can be success-
fully switched between statins without 
compromising care, and physicians in the 
UK extensively use generic simvastatin 
to achieve agreed target lipid levels in 
the Quality and Outcomes Framework to 
help maximise their income.
 - ACEIs/ARBs [5,9,33,42,44,48,49,90,94-
100]: no differences in effectiveness be-
tween ACEIs and ARBs, with prospective 
clinical studies shown that a dry cough 
only occurring in approximately 10% of 
patients prescribed ACEIs and only 2% 
to 3% of patients in ACEI clinical trials 
discontinued their treatment due to a dry 
cough. Patented ARBs can be prescribed 
second line where there are concerns with 
tolerance or side-effects with ACEIs, 
especially as a recent ecological study 
showed outcomes, in terms of the subse-
quent impact of drug treatment on blood 
pressure, were similar whether patients 
were prescribed formulary drugs (includ-
ing generic ACEIs) versus non-formulary 
drugs (including patented ARBs). The 
first generic ARB, losartan, has now been 
launched across Europe with other ge-
neric ARBs recently launched or about to 
be launched further enhancing ARB pre-
scribing efficiency. This especially with 
meta-analyses and patient registry studies 
showing no differences in effectiveness 
authorisation [6,8,10,15,40,81]. The pre-
defined acceptance limits for bioequivalence 
for different batches of generics ensure that 
plasma concentrations vary only by 3-4% 
on average from those of the originator, i.e. 
the same for different batches of the origina-
tor, which is seen as clinically irrelevant in 
the vast majority of situations [81,82]. As a 
result, health authority and health insurance 
company personnel typically assume that if 
two medicines have the same bioavailability 
they should have a similar therapeutic effect. 
This is typically the case even when the ge-
neric is a different salt to the originator with 
initially different indications when first ap-
proved by the European Medicines Agency 
(EMA). This happened with generic clopi-
dogrel despite the efforts of the originator 
company to persuade physicians to continue 
prescribing Plavix® [52,82,83]. This belief 
is strengthened by the continual monitor-
ing of the quality of generics by EMA and 
regulatory authorities in member states, lead-
ing for instance to the withdrawal of some 
versions of generic clopidogrel when there 
were concerns with the manufacturing pro-
cess [52,82]. This is illustrated by two recent 
literature reviews comparing the outcomes 
between generic and originator drugs for the 
treatment of different disease areas [84,85], 
which again failed to show any superiority 
of the originator [82]. The first review, which 
was concerned with medicines for the man-
agement of epilepsy, found no evidence of an 
association between loss of seizure control 
and treatment with a generic drug versus the 
originator with at least three anti-epileptic 
drugs, one of which was phenytoin [84]. 
Subsequent studies have shown that patients 
with epilepsy can be successfully switched 
between different generic versions of the 
same molecule [86]. The second review con-
cerned various treatments for cardiovascular 
disease. This again failed to demonstrate any 
superiority in outcomes for originators com-
pared with generic drugs of the same mol-
ecule [85]. This included drugs with a nar-
row therapeutic index such as propafenone 
and warfarin [85]. Recent published studies 
have also shown that generic and originator 
atorvastatin were equally effective in correct-
ing the lipid profile and reducing the coro-
nary risk in patients with hyperlipidemia and 
increased risk, and both were equally well 
tolerated [87].
Patient care should also not be compromised 
with increased use of generics versus exist-
ing patented products in high volume classes 
such as the proton pump inhibitors (PPIs), 
HMG CoA reductase inhibitors (statins) and 
renin-angiotensin system inhibitor drugs 
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price. Secondly, a review of potential meth-
ods to enhance the prescribing and dispens-
ing of generics versus originators. Thirdly, 
a review of potential methods to enhance 
the utilisation of generics versus patented 
products in a class or related classes. Fourth, 
combining supply- and demand-side mea-
sures in selected case histories to give future 
guidance.
Measures to obtain low 
prices for generics
European countries typically have different 
approaches to the pricing of generics, with 
member States free to develop their own 
national policies for the pricing and reim-
bursement of drugs [11]. However, they can 
be categorised into [1-4,6,8,10,36,37,40-
44,46,47,76, 101-103]:
 - Prescriptive pricing policies (price regu-
lated systems): this includes mandated 
prices for generics such as the “stepped 
price” model in Norway with a maxi-
mum 85% reduction versus pre-patent 
loss prices for high volume generics, and 
France where initially generics have to be 
priced at least 55% below pre-patent loss 
prices to be reimbursed. However, there 
are concerns depending on the level of the 
prescriptive price reductions that generic 
manufacturers will subsequently under-
take appreciable discounting in the dis-
tribution chain to enhance the possibility 
of their generic being preferentially dis-
pensed. As a result, reducing competition 
whilst also reducing potential savings to 
health care systems, especially where the 
price of some generics vary up to 36 fold 
across countries depending on the mole-
cule and country, potentially making some 
policies unsustainable in the long term.
 - Market forces: where there is free pric-
ing. This is typically combined with mea-
sures to enhance the prescribing of gener-
ics versus originators including high INN 
(International Non-proprietary Name) 
prescribing (voluntary or compulsory), 
compulsory substitution or financial in-
centives including additional co-payments 
for a more expensive product than the ref-
erenced price molecule (ATC Level 5).
 - Mixed approach (combination of the 
two): this combines both approaches, 
e.g. in Finland the first generic must be 
priced at least 40% below pre-patent loss 
originator prices to be reimbursed, with 
subsequent generics priced lower to be 
reimbursed along with market force mea-
sures encouraging the prescribing and 
dispensing of the least costly generic. In 
Austria, the first generic must be priced 
Country Measures and their outcomes
France 
(prescriptive 
pricing) 
[2,6,8,10,15]
 • In France the first generics have to be priced at least 55% below pre‑patent loss prices to be reimbursed. Prices 
reduce by a further 7% after 18 months
 • This coupled with multiple policies to enhance the prescribing and dispensing of generics (see text) led to 
annual savings estimated at €1bn in 2007, €0.905bn in 2008 and €1.01bn in 2009
Croatia (mixed 
approach) 
[9,32‑34]
 • First generic must be priced no higher than 70% of the average prices in three countries in order (Italy, France 
and Slovenia); alternatively Spain or Czech Republic
 • Subsequent generics must be priced up to 90% of the last bioequivalent product to be reimbursed with market 
forces including higher co‑payments for more expensive generics helping to lower prices
 • Alongside this instigation of a new reference pricing system for existing drugs (ATC Levels 3 and 4) based on the 
lowest price of products with a market share of at least 5% by expenditure during the preceding 12 months, with 
patients paying the price difference for a more expensive product. Manufacturers can opt to lower prices of their 
other products if problematic, e.g. limited opportunities for substitution such as antiepileptic drugs
These measures, combined with reforms regarding the pricing of new products including price: volume 
agreements, resulted in 47 new products being added to the health insurance reimbursement list between 2009 
and 2010. They also:
 • reduced health insurance expenditure by €0.2bn during the first 6 months of 2010 versus 2009
 • helped stabilise expenditure on drugs for Parkinson’s Disease between 2005 and 2010 despite appreciable 
increases in volumes which included patented add‑on therapies such as ropinirole and pramipexole
Lithuania 
(mixed 
approach) 
[6,9,35,36]
 • The first generic launched must be priced no higher than 30% below the originator, the second generic at 
least 10% lower than the first generic on a pack basis and the third generic 10% lower than the second to be 
reimbursed. Once there are more than 3 manufacturers for the molecule, a maximum list price for the originator 
at 60% above the cheapest generic (2010), dropping to 30% in 2011
 • New generics are automatically included in existing reference price groups for the molecule grouped by INN, 
method of administration, indication and length of action, with the cheapest molecule establishing the reference 
price. Patients have to cover the price difference for a more expensive products themselves
 • Benchmarking prices of generics against other European countries including Bulgaria and Romania
In addition:
 • All reimbursed prescriptions should be written by INN name except biological products, unless the physician 
receives prior approval from the Hospital or Polyclinic Therapeutic Committee
 • Pharmacists must provide pricing information to patients on a computer screen, and dispense the cheapest 
generic, else an initial fine of Ltk100 (€30) with further abuse resulting in the pharmacy no longer able to 
dispense prescriptions on behalf of the Lithuanian Health Insurance Agency
These measures, combined with regulations for new medicines including price: volume agreements, resulted in 
a target reduction of 6% in pharmaceutical expenditure in 2010 vs. 2009, with the number of prescriptions fully 
reimbursed increasing by 9%.
Individually:
 • generic omeprazole in 2009 was 56% below pre‑patent loss prices in 2000 (Expenditure/DDD) mirroring other 
European countries
 • generic simvastatin in 2009 was 83% below pre‑patent loss prices in 2000 (Expenditure/DDD) with prices still 
falling
 • generic atorvastatin in 2009 was 87% below pre‑patent loss prices in 2001
Netherlands 
(mixed 
approach with 
increasingly 
market forces) 
[104‑108]
 • In 2004, a covenant was instigated whereby generics should be priced no higher than 40% below the originator 
for reimbursement, with additional agreements after this to further lower prices
 • Preference pricing policy instigated in 2008 whereby only the cheapest generics would be reimbursed, with 
patients covering the costs for a non‑preferred drug. Tenders were conducted for high volume generics to 
achieve low prices. This resulted in:
 • appreciable price reductions of between 76% to 93% for the 10 largest generics by volume, leading to 
estimated savings of €348mn/year
 • the scheme being extended in 2009 as more generics became available resulting in pharmaceutical 
expenditure stabilizing in the Netherlands in recent years
 • both generic omeprazole and generic simvastatin in 2010 at just 2% of originator pre‑patent loss prices 
(expenditure/DDD)
However, there are concerns regarding the sustainability of pharmacies and the generic industry in the 
Netherlands as a result of the preference pricing policy
Republic 
Srpska (mixed 
approach) [42]
 • In 2006, the reference price for the molecule (ATC Level 5) became the current median price among those 
molecules currently reimbursed and on the market in the Republic Srpska
 • From the beginning of May 2008, the reference price became the lowest priced molecule (ATC Level 5), with 
patients required to cover the difference themselves for a more expensive drug. Market forces, including 
financial and other measures to increase INN prescribing as well as encourage substitution, are expected to 
further drive down generic prices as different generics receive market authorisation
 • Reimbursed expenditure/DDD for PPIs, statins and ACEIs/ARBs decreased by up to 82% in 2010 versus 2004 prices, 
with reimbursed expenditure/DDD for generic omeprazole, simvastatin and ACEIs some of the lowest in Europe
between ARBs for the management of 
hypertension or heart failure when used at 
optimal doses, although typically higher 
doses are needed for heart failure. In ad-
dition, published studies have shown that 
patients can be successfully switched be-
tween ARBs.
OBJECTIVE
The objective of this paper is to review the 
influence of the plethora of measures and ini-
tiatives introduced across Europe in recent 
years to enhance the prescribing and dispens-
ing of generics at low prices. In view of this, 
improve prescribing efficiency in ambula-
tory care especially for drugs in high volume 
classes. In this case, prescribing efficiency is 
defined as drug volumes increasing at a faster 
rate than expenditure where the drugs in each 
class or related class are seen as essentially 
similar in all or nearly all patients. As a result, 
provide guidance to health authorities and 
health insurance companies across Europe as 
they strive to instigate additional measures to 
further enhance their prescribing efficiency to 
meet their goals.
METHODOLOGY
This is a narrative review of papers on the 
influence of generics on increasing prescrib-
ing efficiency. The papers will principally be 
taken from the extensive number of publi-
cations that the co-authors have either been 
involved with or are known to them. Case 
histories will also be included to further il-
lustrate the influence of multiple measures. 
These will again be based on publications or 
internal documents known to the co-authors.
We did not undertake a systematic review 
of published papers concerning generics, as 
this has already been performed by the co-
authors and others. In addition, we did not 
critique the quality of the papers using estab-
lished methodologies as a number of the pa-
pers quoted are reviews rather than primary 
research. However, we believe our approach 
is valid given the extensive experience and 
publications of the co-authors from across 
Europe with instigating measures and initia-
tives to lower the prices of generics as well 
as increase their utilisation versus originators 
and patented products in a class.
RESULTS
These will be divided into four components. 
Firstly, a review of different approaches to 
the pricing of generics from across Europe 
combined with selected case histories which 
illustrate potential ways to achieve low 
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48% below pre-patent loss originator 
prices to be reimbursed, the second ge-
neric 15% below this, and the third ge-
neric 10% below the second. This results 
in 60% below pre-patent loss prices for 
reimbursement (also setting the reim-
bursed price also for the originator). Suc-
cessive generics must be priced at least 
10 cents per pack lower than the previ-
ous generic to be reimbursed, with mar-
To be continued >
price. Secondly, a review of potential meth-
ods to enhance the prescribing and dispens-
ing of generics versus originators. Thirdly, 
a review of potential methods to enhance 
the utilisation of generics versus patented 
products in a class or related classes. Fourth, 
combining supply- and demand-side mea-
sures in selected case histories to give future 
guidance.
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 - Prescriptive pricing policies (price regu-
lated systems): this includes mandated 
prices for generics such as the “stepped 
price” model in Norway with a maxi-
mum 85% reduction versus pre-patent 
loss prices for high volume generics, and 
France where initially generics have to be 
priced at least 55% below pre-patent loss 
prices to be reimbursed. However, there 
are concerns depending on the level of the 
prescriptive price reductions that generic 
manufacturers will subsequently under-
take appreciable discounting in the dis-
tribution chain to enhance the possibility 
of their generic being preferentially dis-
pensed. As a result, reducing competition 
whilst also reducing potential savings to 
health care systems, especially where the 
price of some generics vary up to 36 fold 
across countries depending on the mole-
cule and country, potentially making some 
policies unsustainable in the long term.
 - Market forces: where there is free pric-
ing. This is typically combined with mea-
sures to enhance the prescribing of gener-
ics versus originators including high INN 
(International Non-proprietary Name) 
prescribing (voluntary or compulsory), 
compulsory substitution or financial in-
centives including additional co-payments 
for a more expensive product than the ref-
erenced price molecule (ATC Level 5).
 - Mixed approach (combination of the 
two): this combines both approaches, 
e.g. in Finland the first generic must be 
priced at least 40% below pre-patent loss 
originator prices to be reimbursed, with 
subsequent generics priced lower to be 
reimbursed along with market force mea-
sures encouraging the prescribing and 
dispensing of the least costly generic. In 
Austria, the first generic must be priced 
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reduce by a further 7% after 18 months
 • This coupled with multiple policies to enhance the prescribing and dispensing of generics (see text) led to 
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method of administration, indication and length of action, with the cheapest molecule establishing the reference 
price. Patients have to cover the price difference for a more expensive products themselves
 • Benchmarking prices of generics against other European countries including Bulgaria and Romania
In addition:
 • All reimbursed prescriptions should be written by INN name except biological products, unless the physician 
receives prior approval from the Hospital or Polyclinic Therapeutic Committee
 • Pharmacists must provide pricing information to patients on a computer screen, and dispense the cheapest 
generic, else an initial fine of Ltk100 (€30) with further abuse resulting in the pharmacy no longer able to 
dispense prescriptions on behalf of the Lithuanian Health Insurance Agency
These measures, combined with regulations for new medicines including price: volume agreements, resulted in 
a target reduction of 6% in pharmaceutical expenditure in 2010 vs. 2009, with the number of prescriptions fully 
reimbursed increasing by 9%.
Individually:
 • generic omeprazole in 2009 was 56% below pre‑patent loss prices in 2000 (Expenditure/DDD) mirroring other 
European countries
 • generic simvastatin in 2009 was 83% below pre‑patent loss prices in 2000 (Expenditure/DDD) with prices still 
falling
 • generic atorvastatin in 2009 was 87% below pre‑patent loss prices in 2001
Netherlands 
(mixed 
approach with 
increasingly 
market forces) 
[104‑108]
 • In 2004, a covenant was instigated whereby generics should be priced no higher than 40% below the originator 
for reimbursement, with additional agreements after this to further lower prices
 • Preference pricing policy instigated in 2008 whereby only the cheapest generics would be reimbursed, with 
patients covering the costs for a non‑preferred drug. Tenders were conducted for high volume generics to 
achieve low prices. This resulted in:
 • appreciable price reductions of between 76% to 93% for the 10 largest generics by volume, leading to 
estimated savings of €348mn/year
 • the scheme being extended in 2009 as more generics became available resulting in pharmaceutical 
expenditure stabilizing in the Netherlands in recent years
 • both generic omeprazole and generic simvastatin in 2010 at just 2% of originator pre‑patent loss prices 
(expenditure/DDD)
However, there are concerns regarding the sustainability of pharmacies and the generic industry in the 
Netherlands as a result of the preference pricing policy
Republic 
Srpska (mixed 
approach) [42]
 • In 2006, the reference price for the molecule (ATC Level 5) became the current median price among those 
molecules currently reimbursed and on the market in the Republic Srpska
 • From the beginning of May 2008, the reference price became the lowest priced molecule (ATC Level 5), with 
patients required to cover the difference themselves for a more expensive drug. Market forces, including 
financial and other measures to increase INN prescribing as well as encourage substitution, are expected to 
further drive down generic prices as different generics receive market authorisation
 • Reimbursed expenditure/DDD for PPIs, statins and ACEIs/ARBs decreased by up to 82% in 2010 versus 2004 prices, 
with reimbursed expenditure/DDD for generic omeprazole, simvastatin and ACEIs some of the lowest in Europe
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Measures to enhance the utilisation 
of generics versus originators
A range of measures have been introduced 
in France in recent years to enhance the pre-
scribing and dispensing of generics versus 
originators. These include [2,6-8,10,15]:
 - Physicians:
 - authorities publishing and updating the 
list of generic products available, as 
well as regularly benchmarking ambu-
latory care physicians on their generic 
prescribing rates benchmarked with 
colleagues and providing feedback;
 - introducing Pay for Performance 
(P4P) measures whereby GPs receive 
additional payment for increasing 
the prescribing of generics in a class 
(ATC Level 4) or group of classes 
(ATC Level 3). Classes include anti-
biotics, PPIs, statins, antihypertensive 
drugs as well as antidepressants.
 - Pharmacists:
 - guaranteed the same absolute margin 
for both generic and originator medi-
cines;
ket forces helping to drive prices down 
through IT systems and physician educa-
tion to encourage the prescribing of the 
cheapest branded generic.
Perhaps not surprising, the utilisation of ge-
nerics versus originators is greater in coun-
tries where there is free pricing, with market 
forces used to drive down prices [39]. As a 
result, countries such as Slovenia are looking 
to introduce compulsory generic substitution 
along with reference pricing for therapeutic 
drug groups (cluster of drugs for the same 
therapeutic indication) to further lower prices, 
including generics, to contain costs. A number 
of case histories illustrating the influence of 
the various measures are contained in Table I.
The case histories particularly in Lithuania 
and the Republic Srpska demonstrate that Eu-
ropean countries with small populations can 
introduce multiple reforms including those to 
obtain low prices for generics [36,42]. As a 
result, dispel myths that countries with small-
er populations have difficulties negotiating 
with manufacturers and obtaining low prices 
for drugs [111].
Sweden 
(market forces) 
[3,4,6,8,15, 
109,110]
Compulsory generic substitution was introduced in 2002 unless:
 • the prescriber indicates that the drug should not be substituted on medical grounds
 • substitution may be restricted for reasons such as differences in taste for oral solutions or divided tablets
 • the patient is willing to pay the price difference for a more expensive branded generic originator
In practice, substitution almost always happened helped by an increasing focus on drug costs within the regions 
(counties in Sweden) following devolution of drug budgets and physician acceptance of this reform.
As a result:
 • generic prices fell on average of 40% by the end of 2005 compared with 2002, with prices for high‑volume 
drugs falling further – reaching 4 to 13% of originator pre‑patent loss prices by 2009, helped a comprehensive 
technical support system enabling pharmacies to continually stock the cheapest product with prices reviewed at 
least twice a month by the reimbursement agency (TLV), facilitated by one national pharmacy chain – Apoteket 
AB – owned by and reporting directly to the government (currently TLV reviews the prices of generics once a 
month whilst the availability of generics is typically undertaken daily). The TLV estimated overall savings of €700 
million (>6.97 billion SEK) from 2002 to the end of 2005. Expected savings from the tendering process are 8bn 
SEK/year from 2011 onwards
 • the TLV estimated overall savings of €700 million (>6.97 billion SEK) from 2002 to the end of 2005
However, there were occasions when prices of some generics rose from one month to the next. In addition, there 
is currently competition among community pharmacists in Sweden. Consequently since 2009:
 • all pharmacies are obligated to offer patients the cheapest molecule currently on the market (ATC Level 5) when 
there are substitutable generic medicines available. In return, they received €1/package extra when dispensing 
drugs subject to generic competition
 • there are regular monthly auctions for generics, with the manufacturer with the lowest price wining the auction
However, they must be able to supply the whole market for the entire period. This typically translates into 70% of 
the total sales during the period (almost 80% when the crossed prescriptions are excluded) when the washout 
period and out‑of‑stock situations are factored in
This should lead to further falls in the prices of generics
UK (market 
forces) 
[6,8,10,15,31, 
33,37,38]
 • Introduction of the ‘M’ and ‘W’ (Manufacturer and Wholesaler) scheme in the UK in 2005 resulted in increasing 
transparency in the pricing of generics, as well as discounts and rebates offered by manufacturers to community 
pharmacists to preferentially dispense their generic
 • As a result, there was:
 • an average 32.4% reduction in the prices of generics within the first year of introduction, resulting in a 2% 
reduction in overall pharmaceutical expenditure the year following its introduction. Prior to this, some generic 
manufacturers were offering discounts of up to 80% or more to community pharmacists to preferentially 
dispense their particular generic
 • reimbursed prices (tariff price) and expenditure/DDD for generic simvastatin 2% to 3 % of pre‑patent loss 
originator prices
Consequently, there is typically active monitoring of Drug Tariff prices by Pharmaceutical Advisers to enhance 
potential savings, as well as active monitoring of drug patent expiry dates to identify potential opportunities for 
switching drugs within a class (ATC Level 4) just before or just after generic availability
Table I. Case history approaches of approaches used by countries to lower the prices of generics and their outcome
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 - instigation of annual substitution tar-
gets linked with the national agree-
ment between the pharmacists and the 
Health Insurance Fund.
 - Patients:
 - government promotional campaigns 
to enhance the acceptance of generics 
and INN prescribing;
 - Health Insurance Funds promoting 
generics on the back of reimburse-
ment forms sent to patients;
 - patients must pay the Health Insur-
ance proportion of the cost of a drug 
if they refuse substitution (30% for 
comfort drugs, 65% for the majority, 
and 100% for essential drugs – al-
though 85% of the population have 
supplementary insurance covering 
the difference) and subsequently can 
claim this back. However, if patients 
accept substitution, the pharmacists 
cover these costs themselves and 
claim this back afterwards.
As discussed, these measures, coupled with 
a prescriptive pricing policy for generics, 
led to annual savings estimated at €1bn in 
2007, €0.905bn in 2008 and €1.01bn in 2009 
[15]. The early analysis of the pilot P4P pro-
gramme (Contrat d’Amélioration des Pra-
tiques Individuelles – CAPI) also indicates 
a positive influence on physician behaviour; 
consequently, it has now been extended to all 
GPs in France [63]. In Portugal, the current 
target goal is to reduce NHS expenditure in 
2012 by over 10% versus 2011 levels, and by 
a further 20% in 2013, achieved by introduc-
ing a range of supply- and demand-side mea-
sures. These include for pharmaceuticals:
 - Supply-side measures:
 - pricing of generics - the first generic 
must be lower than 50% than the pre-
patent originator price to be reimbur-
sed. By the time the fifth generic is 
available, its price must be 5% lower 
than the latest generic submitted for 
reimbursement;
 - instigation of a reference price system 
based on the 5 cheapest molecules 
(ATC Level 5), with patients covering 
the additional cost themselves for a 
more expensive molecule;
 - removing/reducing some of the cur-
rent legal/administrative barriers to 
the entry of generics to hasten their 
introduction in Portugal.
 - Demand-side measures:
 - generic advertising campaigns to all 
key stakeholder groups including 
physicians and patients (Figure 1);
 - increasing IT support including elec-
tronic medical prescribing as well as 
other measures to enhance the ratio-
nal use of medicines. These include 
alerts/pop-ups on the cheapest medi-
cinal products available to treat the 
condition. They also include IT tools 
to monitor GP prescribing;
 - therapeutic guidelines (electronic and 
hard copy);
 - information given to the patient in the 
prescription about the amount that 
could be saved if the doctor would 
have chosen the cheapest medicine for 
the condition;
 - increasing patient co-payments by 
reducing NHS contributions of high 
volume ambulatory care drugs, e.g.: 
i)ulcer therapies decreased from 69 to 
37%; ii) anti-inflammatory therapies 
decreased from 69 to 37%; iii) anti-de-
pressants decreased from 95 to 37%.
As a result, the generic market in Portugal 
expanded by16% January to October 2011, 
with costs decreasing by 12%. This favour-
ably impacted on the total market where both 
volumes and costs are now decreasing.
Other examples to increase the prescribing 
and dispensing of generics versus origina-
tors, some of which are described in Table I, 
include:
 - Lithuania, where all reimbursed prescrip-
tions should be written by INN name ex-
cept biological products, unless the phy-
sician receives prior approval from the 
Hospital or Polyclinic Therapeutic Com-
mittee [36];
 - Sweden, where there is currently compul-
sory generic substitution apart from a mi-
nority of situations [3,4,7,8,15,19];
 - United Kingdom, where there is high 
voluntary INN prescribing encouraged 
through education and follow-up ac-
tivities. This current averages over 82% 
across all products and up to 99.5% once 
drugs lose their patent, e.g. generic simv-
astatin [10,15,33,37,38].
Figure 1. Part of the generics advertising campaign to patients
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renin-angiotensin inhibitor system drugs. 
As discussed earlier, the products in each 
of these three classes or related classes are 
seen as essentially similar in all or nearly all 
patients. Consequently, the goal of health au-
thorities and health insurance companies is to 
increase the prescribing of generics in each 
class once available, and restrict the utilisa-
tion of existing patented products. However, 
this is not easy with pharmaceutical compa-
nies investing considerable resources to in-
fluence the prescribing of particularly patent-
ed products, with promotional expenditure 
as high as US$53bn in the US alone in 2004 
[31,115-117].
The ongoing reforms in Portugal described 
earlier also comprise multiple supply- and 
demand-side measures to considerably re-
duce pharmaceutical expenditure in light of 
the current financial situation [118] whilst 
still providing comprehensive health care.
DISCUSSION
We believe we have shown that health au-
thorities and health insurance companies 
have successfully introduced a plethora of 
multiple supply- and demand-side measures 
and initiatives across Europe to appreciably 
improve prescribing efficiency. This is irre-
spective of the size of the population of the 
country. This includes measures to lower the 
price of generics as well as increase their 
utilisation versus originators and patented 
products in the class or related classes. Typi-
cally, multiple measures and initiatives are 
needed to appreciably change prescribing 
behaviour given the considerable resources 
spent by pharmaceutical companies on pro-
motional activities and their known influence 
[120-125].
Consequently, we believe these many re-
forms and initiatives are here to stay particu-
larly in Europe given the current economic 
situation coupled with ageing populations, 
rising patient expectations and the contin-
ued launch of new premium priced drugs. 
As demonstrated (Table II), the increasing 
use of generics at lower costs than patented 
drugs provides considerable opportunities 
for authorities to conserve resources without 
compromising care, especially if the quality 
of generics is maintained through the EMA 
and country regulatory authorities.
As a result, we believe it is inevitable that 
there will be increasing use of generics across 
Europe, especially as more standard drugs 
lose their patents. The alternative is insuffi-
cient funds to cover the costs of increasing 
drug volumes with ageing populations across 
Europe and/or difficulties with funding new 
Class Countries, measures and their influence with increasing prescribing efficiency
PPIs [6‑9,15,38,104] Sweden versus Ireland:
 • multiple demand side measures, including education, economics, and engineering, appreciably 
increased the prescribing of omeprazole in Sweden once generics became available, with stable and 
low utilisation of esomeprazole as a % of total PPI utilisation (<20% on a DDD basis)
 • this compared with Ireland with more limited demand side measures to combat industry activities, 
where utilisation of omeprazole decreased and the utilisation of esomeprazole increased following 
the availability of generic omeprazole, with both approximately 30% of total PPI utilisation in 2007
 • this combined with the measures to lower the prices of generics in Sweden (Table I) resulted in 
reimbursed expenditure for PPIs decreasing by 49% in 2007 vs. 2001 despite utilisation increasing by 
53%. This compares with a 2.6 fold increase in expenditure in Ireland during the same period versus 
a 2.4 fold increase in utilisation
 • as a result, reimbursed expenditure (Euros/1000 inhabitants/year in Ireland (GMS population – 
greater co‑morbidity than the normal population) in 2007 was over 10 fold greater at over €60,000 
versus €5832 for Sweden
Netherlands:
 • multiple demand side measures introduced in the Netherlands, coupled with supply side measures 
to lower generic prices (described in Table 1), led to reimbursed expenditure for the PPIs falling by 
58% in 2010 vs. 2000. This was despite a 3 fold increase in utilisation
Scotland:
 • multiple demand side measures, coupled with supply‑side measures to lower generic prices (Table I), 
resulted in expenditure/1000 inhabitants/year for the PPIs in 2010 at GB£5481 (€6301), 56% below 
2001 levels despite a 3 fold increase in utilisation
 • it is estimated that PPI expenditure in Scotland would have been GB£159mn per year greater in 2010 
– assuming similar overall utilisation coupled with utilisation patterns and their costs kept the same as 
the pre‑patent loss situation
Statins [6‑9,38,43,104] Austria:
 • restrictions limiting the prescribing of patented statins (atorvastatin and rosuvastatin), combined with 
measures to lower the prices of generics and originators (Table I), resulted in a 3% decrease in total 
expenditure for the statins in 2007 versus 2001 despite approximately 2.4 fold increase in utilisation
Sweden versus Ireland:
 • there was a similar situation with the statins, with the utilisation of atorvastatin and rosuvastatin rising 
appreciably in Ireland following the availability of generic simvastatin, accounting for nearly 80% of all 
statin utilisation (DDD basis) in 2007
 • as a result, statin expenditure increased 4.9 fold in Ireland between 2001 and 2007 for the GMS 
population (utilisation increasing 7.3 fold) versus a 39% reduction in Sweden (compared with a 3.2 
fold increase in utilisation)
 • again, reimbursed expenditure (Euros/1000 inhabitants/year) in Ireland (GMS population) in 2007 
was over 10 fold greater than Sweden at over €60,000 versus €5192 for Sweden
Netherlands:
 • multiple demand side measures, coupled with supply side measures to lower generic prices (Table I), 
led to reimbursed expenditure for the statins falling by 14% in 2010 vs. 2000 despite a 3.8 fold 
increase in utilisation
Scotland:
 • multiple demand side measures, coupled with supply‑side measures to lower generic prices (Table I), 
resulted in expenditure/1000 inhabitants/year for the statins in 2010 at GB£11420/1000 inhabitants 
(€13113) only 7% above 2001 levels despite a 6.2 fold increase in utilisation
 • expenditure for the statins would have been GB£290mn per year greater in 2010 assuming similar 
overall utilisation coupled with utilisation patterns and their costs kept the same as the pre‑patent 
loss situation
ACEIs/ARBs [33,44,119] ACEIs and ARBs in Austria, Croatia and Scotland:
 • expenditure (Euros)/1000 inhabitants/year remained relatively stable for the renin‑angiotensin inhibitor 
drugs in Austria, Croatia and Scotland between 2001 and 2007 despite volumes increasing by 
between 69% to 159% during this period through multiple supply‑side (see text) and demand side 
measures
 • multiple initiatives were undertaken in Scotland to limit ARB prescribing including education, 
economics and engineering initiatives
Losartan versus other ARBs in Austria:
 • the prescribing restrictions were relaxed for losartan, but not the other ARBs, following the availability 
of generic losartan
 • this appreciably increased the utilisation of losartan versus other single ARBs slowing down the rate 
of growth in ARB expenditure, with expenditure/DDD for losartan declining by 78% by the end of 
August 2011 compared with pre‑patent loss prices
Losartan versus other ARBs in NHS Bury:
 • the Pharmacy team in NHS Bury instigated multiple measures to increase the prescribing of losartan 
versus other ARBs with generic losartan at appreciably lower prices than patented ARBs. These 
included educational activities, financial incentives as well as active switching programmes from 
other ARBs to losartan
 • the programmes led to estimated savings at over eight times the cost of implementation, helping to 
reach target expenditure goals without compromising care
Table II. Case histories of combined measures amongst European countries and their outcome
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renin-angiotensin inhibitor system drugs. 
As discussed earlier, the products in each 
of these three classes or related classes are 
seen as essentially similar in all or nearly all 
patients. Consequently, the goal of health au-
thorities and health insurance companies is to 
increase the prescribing of generics in each 
class once available, and restrict the utilisa-
tion of existing patented products. However, 
this is not easy with pharmaceutical compa-
nies investing considerable resources to in-
fluence the prescribing of particularly patent-
ed products, with promotional expenditure 
as high as US$53bn in the US alone in 2004 
[31,115-117].
The ongoing reforms in Portugal described 
earlier also comprise multiple supply- and 
demand-side measures to considerably re-
duce pharmaceutical expenditure in light of 
the current financial situation [118] whilst 
still providing comprehensive health care.
DISCUSSION
We believe we have shown that health au-
thorities and health insurance companies 
have successfully introduced a plethora of 
multiple supply- and demand-side measures 
and initiatives across Europe to appreciably 
improve prescribing efficiency. This is irre-
spective of the size of the population of the 
country. This includes measures to lower the 
price of generics as well as increase their 
utilisation versus originators and patented 
products in the class or related classes. Typi-
cally, multiple measures and initiatives are 
needed to appreciably change prescribing 
behaviour given the considerable resources 
spent by pharmaceutical companies on pro-
motional activities and their known influence 
[120-125].
Consequently, we believe these many re-
forms and initiatives are here to stay particu-
larly in Europe given the current economic 
situation coupled with ageing populations, 
rising patient expectations and the contin-
ued launch of new premium priced drugs. 
As demonstrated (Table II), the increasing 
use of generics at lower costs than patented 
drugs provides considerable opportunities 
for authorities to conserve resources without 
compromising care, especially if the quality 
of generics is maintained through the EMA 
and country regulatory authorities.
As a result, we believe it is inevitable that 
there will be increasing use of generics across 
Europe, especially as more standard drugs 
lose their patents. The alternative is insuffi-
cient funds to cover the costs of increasing 
drug volumes with ageing populations across 
Europe and/or difficulties with funding new 
Class Countries, measures and their influence with increasing prescribing efficiency
PPIs [6‑9,15,38,104] Sweden versus Ireland:
 • multiple demand side measures, including education, economics, and engineering, appreciably 
increased the prescribing of omeprazole in Sweden once generics became available, with stable and 
low utilisation of esomeprazole as a % of total PPI utilisation (<20% on a DDD basis)
 • this compared with Ireland with more limited demand side measures to combat industry activities, 
where utilisation of omeprazole decreased and the utilisation of esomeprazole increased following 
the availability of generic omeprazole, with both approximately 30% of total PPI utilisation in 2007
 • this combined with the measures to lower the prices of generics in Sweden (Table I) resulted in 
reimbursed expenditure for PPIs decreasing by 49% in 2007 vs. 2001 despite utilisation increasing by 
53%. This compares with a 2.6 fold increase in expenditure in Ireland during the same period versus 
a 2.4 fold increase in utilisation
 • as a result, reimbursed expenditure (Euros/1000 inhabitants/year in Ireland (GMS population – 
greater co‑morbidity than the normal population) in 2007 was over 10 fold greater at over €60,000 
versus €5832 for Sweden
Netherlands:
 • multiple demand side measures introduced in the Netherlands, coupled with supply side measures 
to lower generic prices (described in Table 1), led to reimbursed expenditure for the PPIs falling by 
58% in 2010 vs. 2000. This was despite a 3 fold increase in utilisation
Scotland:
 • multiple demand side measures, coupled with supply‑side measures to lower generic prices (Table I), 
resulted in expenditure/1000 inhabitants/year for the PPIs in 2010 at GB£5481 (€6301), 56% below 
2001 levels despite a 3 fold increase in utilisation
 • it is estimated that PPI expenditure in Scotland would have been GB£159mn per year greater in 2010 
– assuming similar overall utilisation coupled with utilisation patterns and their costs kept the same as 
the pre‑patent loss situation
Statins [6‑9,38,43,104] Austria:
 • restrictions limiting the prescribing of patented statins (atorvastatin and rosuvastatin), combined with 
measures to lower the prices of generics and originators (Table I), resulted in a 3% decrease in total 
expenditure for the statins in 2007 versus 2001 despite approximately 2.4 fold increase in utilisation
Sweden versus Ireland:
 • there was a similar situation with the statins, with the utilisation of atorvastatin and rosuvastatin rising 
appreciably in Ireland following the availability of generic simvastatin, accounting for nearly 80% of all 
statin utilisation (DDD basis) in 2007
 • as a result, statin expenditure increased 4.9 fold in Ireland between 2001 and 2007 for the GMS 
population (utilisation increasing 7.3 fold) versus a 39% reduction in Sweden (compared with a 3.2 
fold increase in utilisation)
 • again, reimbursed expenditure (Euros/1000 inhabitants/year) in Ireland (GMS population) in 2007 
was over 10 fold greater than Sweden at over €60,000 versus €5192 for Sweden
Netherlands:
 • multiple demand side measures, coupled with supply side measures to lower generic prices (Table I), 
led to reimbursed expenditure for the statins falling by 14% in 2010 vs. 2000 despite a 3.8 fold 
increase in utilisation
Scotland:
 • multiple demand side measures, coupled with supply‑side measures to lower generic prices (Table I), 
resulted in expenditure/1000 inhabitants/year for the statins in 2010 at GB£11420/1000 inhabitants 
(€13113) only 7% above 2001 levels despite a 6.2 fold increase in utilisation
 • expenditure for the statins would have been GB£290mn per year greater in 2010 assuming similar 
overall utilisation coupled with utilisation patterns and their costs kept the same as the pre‑patent 
loss situation
ACEIs/ARBs [33,44,119] ACEIs and ARBs in Austria, Croatia and Scotland:
 • expenditure (Euros)/1000 inhabitants/year remained relatively stable for the renin‑angiotensin inhibitor 
drugs in Austria, Croatia and Scotland between 2001 and 2007 despite volumes increasing by 
between 69% to 159% during this period through multiple supply‑side (see text) and demand side 
measures
 • multiple initiatives were undertaken in Scotland to limit ARB prescribing including education, 
economics and engineering initiatives
Losartan versus other ARBs in Austria:
 • the prescribing restrictions were relaxed for losartan, but not the other ARBs, following the availability 
of generic losartan
 • this appreciably increased the utilisation of losartan versus other single ARBs slowing down the rate 
of growth in ARB expenditure, with expenditure/DDD for losartan declining by 78% by the end of 
August 2011 compared with pre‑patent loss prices
Losartan versus other ARBs in NHS Bury:
 • the Pharmacy team in NHS Bury instigated multiple measures to increase the prescribing of losartan 
versus other ARBs with generic losartan at appreciably lower prices than patented ARBs. These 
included educational activities, financial incentives as well as active switching programmes from 
other ARBs to losartan
 • the programmes led to estimated savings at over eight times the cost of implementation, helping to 
reach target expenditure goals without compromising care
Table II. Case histories of combined measures amongst European countries and their outcome
Measures to enhance the utilisation 
of generics versus patented 
products in a class or related class
A plethora of measures and initiatives have 
been introduced among health authorities and 
health insurance agencies across Europe to 
encourage the prescribing of generics versus 
patented products in a class or related class. 
These can be collated under the 4 Es – name-
ly Education, Engineering, Economics and 
Enforcement, and incorporate [4,6-10,15,33-
38,41-53,63,112]:
 - Education: includes programmes in-
fluencing the prescribing of generics 
through dissemination of material as well 
as monitoring and benchmark activi-
ties. Examples include (i) distribution of 
guidelines, guidance and formularies such 
as the ‘Wise Lit’ in Stockholm, Sweden, 
(ii) academic detailing (iii) monitoring or 
benchmarking of physician prescribing 
habits (iv) encouraging.
 - Engineering activities: are concerned 
with organizational or managerial inter-
ventions, and include (i) prescribing tar-
gets and quality targets such as the P4P 
measures in France and the Better Care/
Better Value indictors for high volume 
disease areas in the UK, (ii) disease man-
agement programmes, (iii) agreed generic 
substitution rates in community pharma-
cies such as those in France.
 - Economics: includes both positive and 
negative financial interventions. Ex-
amples include (i) patients covering the 
additional cost themselves for a more 
expensive drug than the current reference 
priced drug (molecule or class), (ii) finan-
cial incentives to physicians for reaching 
agreed prescribing targets or (iii) finan-
cial penalties for continued high cost pre-
scribing.
 - Enforcement: refers to regulations by 
law. Examples have included (i) compul-
sory generic substitution in Sweden, (ii) 
mandatory INN prescribing in Lithuania 
apart from exempt cases, (iii) prescrib-
ing restrictions such as those for patented 
statins in Austria, Finland, Norway and 
Sweden as well as patented ARBs versus 
typically generic ACEIs in Austria, Croa-
tia, Lithiania and Sweden.
It has typically been found that multiple in-
terventions are needed to appreciably change 
physician prescribing behaviour such as in-
creasing the prescribing of generics within a 
class or related class, and hence prescribing 
efficiency [4,6-9,15,33,37,38,50,113,114]. 
This is illustrated by the case histories in 
Table II for the PPIs, statins and the various 
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